West Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

West Pharmaceutical Services (NYSE:WST) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.07, Zacks reports. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. West Pharmaceutical Services updated its FY 2025 guidance to 6.000-6.200 EPS.

West Pharmaceutical Services Stock Performance

NYSE:WST traded up $15.73 on Friday, hitting $214.84. The stock had a trading volume of 5,020,477 shares, compared to its average volume of 424,824. The stock has a market cap of $15.56 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 19.31 and a beta of 1.01. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. The business’s 50-day simple moving average is $327.86 and its two-hundred day simple moving average is $313.82. West Pharmaceutical Services has a 52-week low of $197.01 and a 52-week high of $400.88.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th were given a $0.21 dividend. The ex-dividend date was Friday, February 7th. This represents a $0.84 annualized dividend and a yield of 0.39%. West Pharmaceutical Services’s payout ratio is 12.46%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on WST shares. Citigroup started coverage on West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price objective on the stock. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and increased their price objective for the company from $350.00 to $390.00 in a research report on Thursday, December 12th. StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Tuesday. KeyCorp dropped their price objective on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Bank of America increased their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $344.00.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.